Mission Bio has introduced a new end-to-end product, Tapestri Genome Editing Solution, for the analysis of genome editing.
The new solution is expected to serve as a better analytical tool to develop next-generation gene-edited therapies by enabling single-cell insights that can impact both efficacy and safety.
Genome editing can lead to complex, heterogeneous mixtures of edits, making it difficult to apply a level of process control over genome-edited cellular products.
By evaluating gene editing outcomes at single-cell resolution, the Tapestri Genome Editing Solution tackles these difficulties.
It also helps capture the co-occurrence of on and off-target edits and zygosity of edits that are not possible with conventional bulk analyses.
Key genome editing researchers and cell therapy developers in both academic and industrial sectors are currently conducting tests on an initial version of the Tapestri Genome Editing Solution.
These experts are offering crucial feedback on the analysis.
Mission Bio chief medical officer Dr Todd Druley said: “The data acquired under the Genome Editing Consortium further demonstrates the Tapestri Platform’s potential as a standard analysis tool within the genome editing community.
“Given the heterogeneous results of gene editing strategies, there is a great need to address both industry and regulatory genome editing concerns with a consistent and highly precise technology for accurately measuring gene editing outcomes and our new offering will be a complete solution to do just that.”
The company plans to release Tapestri Genome Editing Solution later this year.
